Fig. 7

miR-4317 suppressed tumor growth and metastasis in vivo. a Levels of miR-4317 in stable miR-4317 knockdown GLC82 cells (Lenti-inhibitor) and control GLC82 cells (Lenti-vector). b-d Stable miR-4317 knockdown GLC82 cells were subcutaneously injected into nude mice to form solid tumors, and representative images of tumor volumes and weights were analyzed by in vivo luciferase imaging on the last day of analysis (n = 5 for each group). e-g The number of metastatic nodules was observed and quantified in the brains and lungs of mice treated with stable miR-4317 knockdown GLC82 cells or control vector cells by the vein injection method. h-j GLC82 cells were subcutaneously injected into nude mice to form solid tumors and synchronously treated with miR-4317 agomir or miR agomir NC (n = 5 for each group); a 10-nmol miR-4317 agomir as well as the miRNA negative control in 0.1 ml saline buffer were locally injected into nude mice to form a tumor mass once every 5 days for 6 weeks; tumor weight and volume were measured. k, l Immunohistochemical staining of Ki67, FGF9, and CCND2 in tumor tissues dissected from nude mice treated with miR-4317 agomir miR or agomir NC. m, n FGF9 and CCND2 protein expression measured by immunohistochemical staining in 80 NSCLC samples and pair-matched lung tissues. o, p Spearman correlation analysis of the negative correlation between the expression of miR-4317 and FGF9/CCND2. ♦p < 0.05